Cleerly Secures $106M Funding for AI Heart Health Early Detection
Cleerly, a groundbreaking cardiovascular imaging startup, is on a mission to revolutionize early detection of heart disease. In a world where heart attacks often strike without warning, the company’s innovative AI software, developed by cardiologist James Min, aims to identify early-stage coronary artery disease through analyzing CT scans of the heart. Similar to how mammograms and colonoscopies detect breast and colon cancer, Cleerly’s technology has the potential to save countless lives by catching heart conditions before they escalate.
The Need for Early Detection
Heart disease remains the leading cause of death in the United States, claiming countless lives each year. Shockingly, many individuals who suffer from heart attacks are completely unaware of the underlying issues that put them at risk. This lack of awareness underscores the critical importance of early screening and detection methods, which Cleerly seeks to provide through its cutting-edge AI solutions.
Cleerly’s Innovative Approach
Founded in 2017, Cleerly emerged from a clinical program established by Dr. James Min in 2003 at New York-Presbyterian Hospital/Weill Cornell Medicine. The company is currently conducting a large-scale clinical trial to demonstrate the efficacy of its AI-powered screening in identifying heart conditions in individuals who exhibit no symptoms. By surpassing traditional non-invasive methods like blood pressure and cholesterol checks, Cleerly’s technology promises to revolutionize the field of cardiovascular health.
Securing Funding for Growth
Recognizing the immense potential of Cleerly’s groundbreaking technology, investors have flocked to support the company’s mission. Recently, Cleerly announced a monumental $106 million Series C extension round led by Insight Partners and Battery Ventures. This significant funding boost follows a previous $223 million Series C round, showcasing the industry’s confidence in Cleerly’s ability to transform heart health diagnostics.
In a world plagued by the silent threat of heart disease, Cleerly stands at the forefront of innovation, offering hope for early detection and prevention. With the support of leading investors and a team of dedicated professionals, Cleerly’s impact on the field of cardiovascular health is poised to be nothing short of revolutionary.
As someone with a family history of heart disease, I understand the importance of early detection and proactive health management. Cleerly’s groundbreaking approach gives me hope that future generations can live longer, healthier lives free from the shadow of heart-related illnesses. How can we as individuals take charge of our heart health and support initiatives like Cleerly to create a brighter, healthier future for all?